Abstract P-glycoprotein (P-gp, multidrug resistance 1 (MDR1)) overexpression confers multidrug resistance to cancer cells, and P-gp in cell lines transfected with MDR1 or selected with chemotherapeutics significantly affect the anticancer drug efficacy.
vincristine, doxorubicin and daunorubicin (Kartner, Evernden-Porelle, Bradley, & Ling, 1985) . Mouse fibroblast NIH 3 T3 cells stably transfected with human MDR1 cDNA showed resistance to colchicine, vinblastine and doxorubicin (Ueda, Cardarelli, Gottesman, & Pastan, 1987) .
However, endogenous P-gp expression affecting the efficacy of anticancer drugs is unclear, although in pharmaceutical industries, cancer cell line panels consisting of well-defined tumor cell lines without enforced expression of MDR1 or its induction by selection have been used frequently to screen for anticancer drugs (Niu & Wang, 2015; Shoemaker, 2006) . In drug discovery and development, the current standard procedure often starts with in vitro cell culture-based tests to screen for the efficacy of drugs, and only approximately 10% of the drugs successfully pass through clinical development (Edmondson, Broglie, Adcock, & Yang, 2014) . Accurate and efficient in vitro screening of anticancer drugs is essential for more successful clinical trials; however, whether clinically promising drug candidates are excluded during screening by using cancer cell line panels due to native P-gp remains unclear. With regard to the impact of breast cancer resistance protein (BCRP), which also confers multidrug resistance (Nakanishi & Ross, 2012) , we have recently reported that the in vitro efficacy of anticancer drugs could be significantly affected by BCRP in cancer cell lines that highly express endogenous BCRP (Washio, Nakanishi, Ishiguro, Yamamura, & Tamai, 2018) .
The Cancer Cell Line Encyclopedia (CCLE) provides public access to the mRNA expression data of approximately 1000 cancer cell lines (Barretina et al., 2012) . Endogenous MDR1 expression was found to largely vary if the CCLE database was used to examine the mRNA expression levels of MDR1 in cancer cell lines ( Figure 1a and Supplemental Table S3 ). The present study assessed the impact of P-gp expression on the efficacy of anticancer drugs using several cancer cell lines displaying varied levels of endogenous P-gp expression. Among the cancer cell lines in the CCLE, all cell lines used in this study were selected from colon cancer-derived cells to avoid an effect caused by the origin of tissues. CW-2, CL-11, CL-40, C2BBe1 and RKO cells were selected based on mRNA expression levels of MDR1 ( Figure 1a and Supplemental Table S3 ). Furthermore, porcine kidney epithelial (LLC-PK1) cells with enforced expression of human MDR1 (LLC-CoL) were used as a positive control for the experiments. 
| Cell culture
The LLC-PK1 cells were obtained from the Japan Health Science
Research Resources Bank (Osaka, Japan). The LLC-GA5-COL150
(LLC-CoL) cells and CW-2 cells were obtained from Riken BioResource
Center (Tsukuba, Japan). The LLC-CoL cells were established by transfection of human MDR1 cDNA into LLC-PK1 cells Ueda et al., 1992 
| Gene expression analysis and data normalization
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). The yield of extracted RNA was measured spectrophotometrically at 260 nm. For first-strand cDNA synthesis, 500 ng of total RNA was reverse-transcribed in a final volume of 50 μl following the protocol for the ReverTra Ace qPCR RT Master Mix (Toyobo, Osaka, Japan). Subsequently, 1 μl of cDNA was used for quantitative realtime polymerase chain reaction (PCR) by the CFX384 Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). The assay identification numbers of inventoried TaqMan real-time PCR analysis of human MDR1, human BCRP, human β-actin, porcine MDR1 and porcine β-actin genes were Hs00184500_m1, Hs01053790_m1, Hs99999903_m1, Ss03373435_m1, and Ss03376563_uH, respectively (Applied Biosystems, Carlsbad, CA, USA). The assays were performed as technical triplicates. Gene expression data were normalized to β-actin as an endogenous control that was quantified in the same sample. Relative expression differences were calculated using the comparative ΔΔC t method (Livak & Schmittgen, 2001 ). 
| Fluorescence activated cell sorting analysis

| Western blot analysis
For western blot analysis, crude membrane fractions were prepared from human colon cancer cell lines and LLC cells based on the method of Gant et al. (1991) . The protein concentrations in the fraction were determined using the method of Lowry, Rosebrough, Farr, and Randall (1951) , with bovine serum albumin as a standard. The membrane fraction was dissolved in Laemmli sample buffer with 
| Cell proliferation assay
The cells were seeded onto 96-well plates at a density of 1500 cells/well. On the following day, anticancer drugs were added at different concentrations with or without 1 μM zosuquidar. After 72 h incubation, the cell density was determined using the sulforhodamine B assay in accordance with reported procedures (Vichai & Kirtikara, 2006) . Briefly, the cells were fixed by adding 10% trichloroacetic acid.
The plates were washed with water and air-dried and 0.057% sulforhodamine B solution was added to each well. The plates were incubated for 30 min at room temperature and rinsed with 1% acetic acid to remove unbound dye. The well was added with Tris base solution (10 mM) to solubilize the protein-bound dye, and optical density (OD) at 540 nm was measured using a microplate reader. Assays were performed as technical triplicates.
| Uptake study using colon cancer cell lines and LLC-CoL cells
The cells were seeded into 24-well plates at a density of 1 × 10 5 cells/well. On the following day, a transport study was conducted as described previously (Hirano, Maeda, Shitara, & Sugiyama, 2004) 2.9 | mRNA quantification after treatment with anticancer drugs
The cells were seeded into 24-well plates at a density of 8900 cells/well. The following day, the cells were exposed to anticancer drugs at the indicated concentrations for 72 h. RNA isolation, reverse transcription and quantitative real-time PCR were performed as described in the previous section.
| Data analysis
The uptake ratio (UR) was calculated using the following equation:
where Uptake +ZSQ and Uptake -ZSQ are uptake clearances with or without zosuquidar, respectively. 
where x and E are the drug concentration and observed percentage of control cell growth, respectively; E min and E max are the percentages of cell growth when x is infinity and 0; respectively, and H is the slope factor.
The resistance ratio (RR) was calculated using the following equa- Table S1 ).
3.2 | Subcellular localization of the P-gp protein in colon cancer cell lines and LLC cells
The subcellular localization of the P-gp protein was examined in colon cancer cell lines and LLC cells using confocal immunofluorescence microscopic analysis. The Na + /K + -ATPase protein was co-stained with P-gp as a plasma membrane marker. In LLC-CoL, CL-11, and C2BBe1 cells, P-gp protein was mainly detected in the plasma membranes. In CW-2 cells, P-gp protein was expressed in the plasma membranes, and strong signals of P-gp protein were also detected in the cell cytoplasm. P-gp protein was rarely detected in LLC-PK1, CL-40 and RKO cells (Figure 2 ).
| EC 50 values of anticancer drugs with and without ZSQ in LLC cells
Ten anticancer drugs that are substrates of P-gp and have different modes of action were selected (Table 1) , and the EC 50 values of these drugs were evaluated with and without a P-gp inhibitor, zosuquidar, in LLC-PK1 and LLC-CoL cells. Zosuquidar was used as a selective P-gp inhibitor (Fuchs, Kishimoto, Gansser, Tanswell, & Ishiguro, 2014; Thomas & Coley, 2003) to evaluate the impact of P-gp inhibition alone. The RR was calculated in each cell line. All ten anticancer drugs inhibited the growth of LLC-PK1 and LLC-CoL cells in a concentrationdependent manner. Although the RRs of paclitaxel (2.1) and everolimus (2.1) were > 2, the RRs of the remaining eight anticancer drugs were < 2 in LLC-PK1 cells, wherein endogenous P-gp expression level was very low (Supplemental Table 1 ). Therefore, the RR of > 2 was considered to be a significant effect by P-gp inhibition. The RR of lapatinib was < 2, whereas the RRs of paclitaxel, cabazitaxel, vinorel- 
| Relationship between URs and P-gp protein expression in colon cancer cell lines and LLC-CoL cells
To 
| Relationship between RRs and P-gp protein expression in colon cancer cell lines and LLC-CoL cells
The relationship between the resistance ratios of paclitaxel, vinorelbine, doxorubicin and mitoxantrone and protein expression levels of P-gp in plasma membrane determined by FACS analysis in five colon cancer cell lines and LLC-CoL cells was examined. Figure 4 shows the results. Although a clear correlation between the RRs and protein expression levels of P-gp was not observed, CW-2 and CL-11 cells that highly express P-gp showed RRs of > 2 in paclitaxel and vinorelbine. The relationship between the expressions of mRNA and protein (Figures 1b and 1c) , and protein subcellular localization (Figure 2) was examined because the P-gp protein is functional as a drug efflux pump when expressed in the plasma membranes. With regard to Pgp protein expression in CL-40 cells, P-gp protein was detected using FACS analysis but not western blot analysis. This may be caused by the differences in the P-gp antibodies used, which were clones C219 and 17F9 for western blot and FACS analyses, respectively, and by the difference in protein measurement methods. However, the corre- FACS and western blot analysis, the P-gp protein was localized not only in the plasma membrane but also inside CW-2 cells and was hardly detected in CL-40 cells (Figure 2 ). For subcellular localization of P-gp, P-gp is reported to be localized not only in the plasma membrane but also in the endoplasmic reticulum, Golgi body, endosomes and lysosomes because these are the sites of P-gp synthesis (endoplasmic reticulum), modification (Golgi body), trafficking/recycling (endosomes) and degradation (lysosomes) (Fu & Arias, 2012; Fu, Bebawy, Kable, & Roufogalis, 2004) . Therefore, P-gp is localized not only in the plasma membrane but also in these organelles in CW-2 cells. The discrepancy between protein and mRNA expression of Pgp in CL-40 cells can be partly explained by post-transcriptional regulation of P-gp. For example, microRNA-145 was recently reported to be involved in the regulation of P-gp protein expression in intestinal epithelial cells. In that report, microRNA-145 was downregulated in colon cancer cell lines; Caco-2 cells increased P-gp protein expression and P-gp-mediated efflux activity of rhodamine 123 but did not alter the MDR1 mRNA level (Ikemura et al., 2013 MDR1 mRNA at higher levels than that in CL-11 cells (Supplemental Table 3 ). Thus, cancer cell lines with higher mRNA expression levels of MDR1 are limited, although they are not neglected.
| Relationship between RRs and URs in colon cancer cell lines and LLC-CoL cells
Because P-gp might be induced during exposure to anticancer drugs in the present study, such an effect was examined in colon cancer cell lines after treatment with paclitaxel, vinorelbine, doxorubicin and mitoxantrone for 72 h at concentrations around EC 50 values (Supplemental Table 2 ). Certain increases in MDR1 mRNA expression were observed in the cancer cell lines investigated, and the largest increase in MDR1 mRNA expression was observed in CL-40 cells in all four drugs. However, the rank of MDR1 mRNA expression levels among the colon cancer cell lines used in this study did not change much before and after treatment with these anticancer drugs. Thus, no significant changes in P-gp expression were observed after incubation with anticancer drugs, which likely affected the RRs of these drugs.
With regard to the relationship between RRS of anticancer drugs and P-gp protein expression levels (Figure 4 ), cell lines with high expression levels of P-gp showed RRs > 2 in some anticancer drugs;
however, a clear correlation was not observed. In the present study, the RRs of doxorubicin were > 2 in CL-11 and C2BBe1 cells although that in CW-2 cells was < 2. Doxorubicin is a substrate of not only P-gp but also other efflux transporters, such as BCRP (Saeed, Kadioglu, Khalid, Sugimoto, & Efferth, 2015) and multidrug resistanceassociated protein 1 (Wei et al., 2012) . BCRP might be partly responsible for the observed resistance because the mRNA expression level of BCRP was relatively high in CL-11 and C2BBe1 cells (Supplemental Table 1 ). The RRs of mitoxantrone in CL-40 and RKO cells, which rarely express P-gp protein, was 2.8 and 2.3, respectively.
Mitoxantrone is also a substrate of BCRP (Miyake et al., 1999) and multidrug resistance-associated protein 1 (Morrow et al., 2006) .
Endogenous transporters other than P-gp and BCRP may contribute to this resistance because the BCRP mRNA expression levels in CL-40 and RKO cells were low (Supplemental Table 1 ).
P-gp is likely involved in the regulation of cellular accumulation of paclitaxel, vinorelbine and doxorubicin because the URs of these anticancer drugs increased with increased P-gp protein expression levels in colon cancer cell lines and LLC-CoL cells (Figure 3 ). Under this condition, the resistance ratio of paclitaxel increased with increased uptake ratio (Figure 5a ), but an apparent correlation between the resistance ratios and uptake ratios of the remaining three drugs was not observed. Accordingly, the resistance ratios of anticancer drugs might be explained better not by apparent intracellular concentrations but by intracellular local concentrations close to their pharmacological target.
With regard to the impact of endogenous metabolic enzymes on the results, paclitaxel is mainly metabolized by cytochrome P450
(CYP) 3A4 and CYP2C8 (Sonnichsen et al., 1995) , vinorelbine by CYP3A4 (Kajita, Kuwabara, Kobayashi, & Kobayashi, 2000) , and mitoxantrone by CYP2E1 (Rossato et al., 2013) . From the CCLE database, the signal intensity of CYP3A4, CYP2C8, and CYP2E1 in colon cancer cell lines used in the present study is < 100, suggesting very low mRNA expression levels of the enzymes in these cell lines. Therefore, the EC 50 (Table 2) Table 4 ). The comparison showed that the mRNA expression levels of MDR1 in > 97% of cancer biopsies were lower than those in CL-11 cells, wherein significant decreases in EC 50 values of several anticancer drugs were observed when P-gp was inhibited.
The MDR1 mRNA expression in most cancer biopsies was comparable or lower than that in C2BBe1 and RKO cells, wherein significant alterations in EC 50 values were not observed due to P-gp ( Figure 6 and Supplemental Table 4 ). However, this does not necessarily mean that the shift of in vivo efficacy caused by P-gp-mediated efflux in cancer tissues can be ignored. Although certain increases in MDR1 mRNA expression were observed in colon cancer cell lines exposed to anticancer drugs (Supplemental Table 2 ), > 90% of the cancer biopsies shown in Figure 6 were from patients who did not undergo chemotherapy before surgical resection, based on clinically annotated expO information (accession number: GSE2109; Gene Expression Omnibus).
Therefore, it should be kept in mind that MDR1 expression levels in cancer tissues after chemotherapy might be increased. In addition, cancer tissues consist of heterogeneous cells, and P-gp is highly expressed in cancer stem cells that are considered responsible for the tumorigenic process (Dean, Fojo, & Bates, 2005) , whereas MDR1 expression levels in cancer biopsies shown in Figure 6 represent an average across heterogeneous cells, including cancer stem cells and other cell types.
| CONCLUSION
Our results suggested that the in vitro efficacy of anticancer drugs on the proliferation of colon cancer cells was significantly affected by Pgp in cancer cell lines abundantly expressing P-gp, accounting for 1.5% of cancer cell lines of all cancer types and 14.5% of colon cancer cell lines in CCLE. Therefore, when cancer cell lines with abundant Pgp expression are used for the screening of anticancer drugs, the effect of P-gp should be carefully evaluated, considering P-gp expression in cancer cell lines and patient-derived malignant tissues, to avoid erroneous selection of drug candidates. In addition, the degree of functional P-gp protein expression at the plasma membranes of cancer cell lines is possibly overestimated from mRNA expression levels and from protein expression levels in crude membrane fractions. Therefore, expression levels of P-gp protein at the plasma membranes are also important for detailed assessment of anticancer drug development.
FIGURE 6
Comparison of relative mRNA expression levels of MDR1 to β-actin between cancer biopsies and cancer cell lines. mRNA expression levels of MDR1 and β-actin in 2157 cancer biopsies and cancer cell lines used in this study, represented as signal intensity of microarray analysis, were obtained from expO and CCLE, respectively, and compared (closed circle, cancer biopsies and open square, colon cancer cell lines). The SI of MDR1 and β-actin, relative SI of MDR1 to β-actin, and derivation of each cancer biopsy are shown in Supplemental  Table S4 
